{'fraction_non_alphanumeric': 0.023125996810207338, 'fraction_numerical': 0.005582137161084529, 'mean_word_length': 5.092233009708738, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effects of enalapril and taurine on left ventricular hypertrophy and arrhythmia in renovascular hypertensive rat].

The effects of enalpril (Ena, 6 mg.kg-1) and taurine (Tau, 30 mg.kg-1) on left ventricular hypertrophy (LVH) and ventricular arrhythmia were studied in two-kidney, one clip renovascular hypertensive rats (RHR). From the 9th week after operation, Ena and Tau were given per oral daily for 9 weeks. These drugs significantly decreased the systolic arterial pressure and the weight of the left ventricle. Combination of both drugs was found to reduce the blood pressure further than either drug used alone. Arrhythmias induced by trains of electrical stimuli were more frequent in working hearts isolated from RHR than that from normotensive rats. Ena and Tau could decrease the incidence of this arrhythmias in RHR. The calcium content in the myocardial mitochondria in RHR was increased compared with that in normotensive rats. Treatment with Ena and Tau reduced this increase significantly. These results suggest that chronic therapy with Ena and Tau can induce an attenuation of systemic arterial pressure and reduce the propensity of RHR heart to arrhythmogenesis by limiting cardiac hypertrophy and calcium overload of the myocardium.